SCHEMBL7754545

SCHEMBL7754545

CC1(C)CCC(C)(C)c2cc(C34CC3CCC4=Cc3ccc(C(=O)O)cn3)ccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 16/20 0.50
RARB P10826 8/20 0.50
RARG P13631 8/20 0.50
RARA P10276 7/20 0.50
CYP26A1 O43174 4/20 0.43
CYP26B1 Q9NR63 3/20 0.43
RXRB P28702 7/20 0.43
RXRG P48443 5/20 0.43
PPARG P37231 1/20 0.43
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
GMNN O75496 1/20 0.41
USP2 O75604 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
POLB P06746 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7754537 1.00 RXRA (0.50) RXRARARBRARGRARACYP26A1
SCHEMBL7754746 0.89 RXRA (0.57) RXRARARBRARGRARACYP26A1
SCHEMBL7754748 0.89 RXRA (0.57) RXRARARBRARGRARACYP26A1
SCHEMBL7755954 0.85 RXRA (0.53) RXRARARBRARGRARACYP26A1
SCHEMBL7755977 0.85 RXRA (0.53) RXRARARBRARGRARACYP26A1
SCHEMBL7757701 0.78 RXRA (0.47) RXRARARBRARGRARACYP26A1
SCHEMBL7757697 0.78 RXRA (0.47) RXRARARBRARGRARACYP26A1
SCHEMBL7756532 0.78 RXRA (0.51) RXRARARBRARGRARACYP26A1
SCHEMBL7756541 0.78 RXRA (0.51) RXRARARBRARGRARACYP26A1
SCHEMBL7754968 0.74 RARB (0.53) RXRARARBRARGRARACYP26A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010034448-A1 New compounds, their preparation and use MURRAY ANTHONY (GB) 2001-10-25 US claimed
EP-1077920-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2001-02-28 EP claimed
WO-1999058487-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1999-11-18 WO claimed
US-20010034448-A1 New compounds, their preparation and use MURRAY ANTHONY (GB) 2001-10-25 US disclosed
EP-1077920-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2001-02-28 EP disclosed
WO-1999058487-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1999-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034448-A1 New compounds, their preparation and use GPR119, SLC5A1, SLC5A2 RXRA 765/4885RARB 1627/4885RARG 1630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.